Introduction
============

Allergic diseases have become a major public health problem over the past few decades. The prevalence of eczema (atopic dermatitis), food allergy, and asthma have all increased dramatically during this time, particularly in Western society. It is believed that between 20 and 30% of individuals living in Western countries suffer at least one form of allergic disease (Zuercher et al., [@B159]). The impact on health care systems and society in general is significant, with allergic disease one of the most common causes of chronic illness, hospital admissions as well as school absenteeism (Su et al., [@B128]). Furthermore, the emotional and psychological burden on parents and families is substantial (Beattie and Lewis-Jones, [@B10]). Parents of children with food allergy have reported a diminished quality of life compared to parents of children with rheumatological conditions, indicating a substantial psychological burden associated with these types of diseases (Primeau et al., [@B106]).

Allergic diseases are characterized by an inappropriate T-helper (Th)-2 cell immune response to environmental or food antigens (Zuercher et al., [@B159]). Activation of this response leads to the secretion of IL-4, IL-5, and IL-13 and the production of allergen-specific IgE. In the classical paradigm, the induction of Th2 cytokine responses also act to suppress Th1 activity (mainly through IFN-γ) which helps maintain the allergic phenotype. Stability of this Th1/Th2 balance is also regulated at the gene level through the relative functions of the GATA-3 (Th2) and T-bet (Th1) transcription factors. However, novel insights into dendritic cell (DC) and regulatory T cell (Treg) biology have revealed important critical effector functions of these populations in the control of allergic responses. Several studies have shown that allergic individuals have reduced Treg numbers and function (Shreffler et al., [@B122]; Palomares et al., [@B99]), while mutations in the Treg transcription factor FoxP3 results in severe immune-mediated diseases (Goodman et al., [@B51]).

The mechanisms that drive the development of allergic disease in early life are yet to be fully understood. One of the more widely recognized ideas relates to intestinal microbiota, where the composition and profile of commensal bacteria interact with the developing immune system. Such interactions can influence immune maturation, potentially leading to Th2-polarized allergic responses. As such, prophylactic or therapeutic strategies that target intestinal microbiota have been the subject of intense scientific research. This review article will discuss the critical function of intestinal microbiota and the evidence for the beneficial effects of probiotics in the prevention and/or treatment of allergic disease.

Hygiene Hypothesis, Intestinal Microbiota, and Immune Development
=================================================================

Reduced exposure to microbes early in life is suggested to be one of the main mechanisms to account for the increasing prevalence of allergic diseases over the past few decades. Commonly referred to as the "hygiene hypothesis," this was originally described by Strachan ([@B126]) and associated reduced microbial contact with increased incidence of hay fever. Today, reduced microbial exposures (and the rise in allergic conditions) have been attributed to Western lifestyle factors such as diet, antibiotic use, vaccinations, reduced household size, and improved hygiene. Epidemiological studies have shown that children raised on farms during early life have a reduced risk of developing allergic disease such as eczema or asthma (Riedler et al., [@B112]), while prenatal farm exposure modulates atopic sensitization later in life (Ege et al., [@B40]).

The human intestinal microbiota represents the most significant microbial exposure for the developing infant. As many as 10^15^ microbes consisting of 1,000 different strains are said to colonize gastrointestinal tract (GIT; Molloy et al., [@B88]). Under normal conditions, these bacteria have beneficial roles to the host such as digestion, immune development, and the control of intestinal epithelial cell growth and differentiation (Martin et al., [@B84]). Commensal bacteria are also important in the fermentation of undigestible dietary fibers, a process which produces large quantities of short-chain fatty acids in addition to the release of essential vitamins (Cummings and Macfarlane, [@B31]).

Colonization by commensal bacteria occurs immediately after birth and continues throughout the first year of life (Arboleya et al., [@B5]). Acquisition of intestinal microbiota can be influenced initially by mode of delivery, maternal microbiota as well as host genetic factors and later by breastfeeding and other environmental factors (Penders et al., [@B102]; Bisgaard et al., [@B12]; Fallani et al., [@B42]; Bezirtzoglou et al., [@B11]; van Nimwegen et al., [@B143]; Azad and Kozyrskyj, [@B7]).

One of the most important functions that intestinal microbiota have is development of the host immune system. It provides the largest source of antigenic stimuli that assists the programming of postnatal immunity through maturation of the gut-associated lymphoid tissue (GALT) while promoting tolerogenic responses to innocuous antigens, including foods. This is primarily achieved via mucosal antigen sampling by pattern recognition receptors (PRRs) expressed on intestinal epithelial cells and innate immune cells (Rautava and Walker, [@B109]). These specialized receptors bind to microbial-associated molecular patterns (MAMPs) that are expressed on a variety of commensal micro-organisms (Amdekar et al., [@B3]). An important member of the PRRs is the Toll-like receptors (TLR) that recognize a range of MAMPS such as lipoteichoic acid (TLR2) and lipopolysaccharide (TLR4) on Gram-negative and Gram-positive bacteria, respectively (Bauer et al., [@B9]). These signals delivered by commensal bacteria to TLRs determine the nature of the immune response and results in a combination of regulatory and inductive effector functions involving DCs, Treg, chemokines, and cytokines to prevent Th2-type allergic responses as well as other inflammatory diseases (Braga et al., [@B22]; Rutella and Locatelli, [@B117]).

Germ-free (GF) mice have provided the best evidence for the role of microbiota on the GALT, as these mice have extensive defects in GALT development. A number of studies have shown that GF mice have reduced intraepithelial lymphocytes, Peyer's patches with impaired germinal center development as well as fewer IgA secreting plasma cells and CD4+ T cells in the lamina propria (Bandeira et al., [@B8]; Macpherson et al., [@B80]; Martin et al., [@B84]). Reconstitution with various microbial species can restore GALT function in these mice, further supporting the role of microbiota in immune development (Rakoff-Nahoum et al., [@B107]). Furthermore, while GF mice do not develop tolerance to parenterally administered antigen owing to a lack of Treg cells, the oral introduction of microbes was able to establish tolerance (Bruzzese et al., [@B25]). A recent study found that GF mice had decreased pro-IL-1β levels compared to wild type, suggesting an impaired ability to promote Th17 cells essential for host defense (Shaw et al., [@B120]). Furthermore, reconstitution with segmented filamentous bacteria, clostridia and *Alcaligenes* was able to stimulate IgA production in GF mice (Talham et al., [@B131]; Umesaki and Setoyama, [@B140]; Obata et al., [@B93]). Moreover, when GF mice were given a high oral dose of ovalbumin (OVA) followed by a systemic challenge to induce tolerance, the Th2 response was not affected; however reconstitution with *Bifidobacterium infantis* in these mice was sufficient for oral tolerance to occur (Sudo et al., [@B129]). Also, antibiotic-treated mice had altered microbiota that was associated with an increased severity in airway inflammation as well as reduced Treg numbers in the colon (Nagler-Anderson, [@B90]; Russell et al., [@B116]). It is reported that the composition of intestinal microbiota may not be able to be restored to its pre-treatment state following antibiotic use (Blaser, [@B16]; Dethlefsen and Relman, [@B35]). These data highlight the important role of microbiota in immune development and the potential for immune dysregulation such as allergy and autoimmunity when there is intestinal dysbiosis (Sjogren et al., [@B124]; Larsen et al., [@B74]; Vijay-Kumar et al., [@B144]; Bisgaard et al., [@B13]).

A relationship between intestinal microbiota and allergic disease is well-established (Bisgaard et al., [@B13]; Johansson et al., [@B62]; van Nimwegen et al., [@B143]). Infants with allergic parents are at least twice more likely to develop allergic diseases than non-allergic parents (Dold et al., [@B37]; Bisgaard et al., [@B13]). Several epidemiological studies have reported that microbiota differences exist between allergic and non-allergic infants as well as between countries with high or low allergy prevalence rates (Bjorksten et al., [@B14], [@B15]; Kalliomaki et al., [@B63]; Watanabe et al., [@B148]). In a recent study by Johansson et al. ([@B62]) infants from non-allergic parents were more frequently colonized by healthy lactobacilli, suggesting a role for maternal microbiota in protection from allergic disease. Other early studies have shown that healthy infants are usually colonized with infant-type *B. longum* and *B. breve* species while infants with eczema are more frequently colonized with adult-type *B. adolescentis* (He et al., [@B54]; Ouwehand et al., [@B98]). Previous studies have also found reduced microbial diversity, accompanied with lower numbers of *lactobacilli* and *bifidobacteria*, and early life colonization by *Staphyloccocus aureus* and *Clostridum difficile* were associated with the development of allergic disease later in life (Penders et al., [@B101]; Sjogren et al., [@B124]).

The ability of intestinal microbiota to influence immune development has led to novel interventions that exploit these microbiota differences in allergic individuals. In recent years, probiotic bacteria have been used with some success in preventing allergic disease in high-risk infants.

Probiotics
==========

The WHO/FAO (Food and Agriculture Organization of the UN) define probiotics as "live micro-organisms, which when administered in adequate amounts, confer a health benefit on the host" (WHO, [@B152]; Reid, [@B110]). The identification and use of probiotics date back to the early twentieth century (Shortt, [@B121]; Anukam and Reid, [@B4]). Professor Elie Metchnikoff, considered the grandfather of modern probiotics, observed that the regular consumption of lactic acid bacteria in fermented dairy products, such as yogurt, was associated with enhanced health and longevity in Bulgarian peasants (Anukam and Reid, [@B4]). At the time, it was believed that fermented milk contained lactic acid bacteria that decreased the pH of the gut and suppressed the growth of proteolytic bacteria (harmful bacteria). Since then, probiotic research as increased exponentially and the benefits of probiotics have been demonstrated in a number of studies for allergy, diarrheal diseases, and inflammatory conditions.

The history of probiotic use together with the wide availability of probiotic supplements over the counter suggests a high degree of safety in humans. Indeed, probiotics are demonstrated to be safe when given to both infants and adults (Tang, [@B132]). In general, probiotic bacteria need to fulfill several ideal criteria in order to elicit their beneficial effects, summarized in Table [1](#T1){ref-type="table"} (Tuomola et al., [@B139]). In taxonomy terms, the most commonly used probiotic bacteria are species of the genera *Lactobacillus* and *Bifidobacterium*. However, probiotic effects are strain and species-specific, and their biological activity can vary depending on the selected probiotic (Licciardi and Tang, [@B76]). Therefore, careful consideration should be given to the probiotic strain selected for use, and should be based on supporting *in vitro* and *in vivo* data.

###### 

**Characteristics of an ideal probiotic**.

  Characteristic              Functional advantage
  --------------------------- --------------------------------------------------------------------
  Local GIT environment       Resistance to pH, bile, and digestive enzymes
  Epithelial cell adherence   Prevent binding of pathogens or food antigens
  Human origin                Increased likelihood of biological effectiveness
  Anti-microbial activity     Direct toxicity to harmful bacteria, viruses, fungi, and parasites
  Safety                      Well-tolerated, important for clinical use

*GIT, gastrointestinal tract*.

Probiotic Mechanism of Action
=============================

There are several mechanisms by which probiotics are proposed to exhibit beneficial effects on the host and these can be broadly classified as microbiological, epithelial, or immunological in nature (Figure [1](#F1){ref-type="fig"}; Oelschlaeger, [@B94]). Firstly, probiotic bacteria are able to modulate the composition of intestinal microbiota. It has been shown in recent studies that supplementation with probiotic bacteria such as *Lactobacillus rhamnosus* GG (LGG) or *L. casei* can modulate the composition of intestinal microbiota of allergic infants by reducing pathogenic bacteria such as *clostridia* while enhancing or maintaining beneficial *bifidobacteria* levels in the stool (Lahtinen et al., [@B72]; Klewicka et al., [@B69]). This is primarily achieved through changes in the intestinal lumen environment such as lowering the pH level and competition for nutrients that result in physiologically restrictive conditions for the growth of pathogenic bacteria (Asahara et al., [@B6]; Todorov et al., [@B138]). Probiotics can also compete with other micro-organisms for binding to specific receptors on host epithelial cells, thereby preventing potential pathogen invasion (Mukai et al., [@B89]; Setia et al., [@B119]). Transient colonization of the GIT by *Bifidobacteria* have been previously demonstrated as early as 1 week after supplementation (Langhendries et al., [@B73]) indicating that these effects can be induced rapidly. Moreover, *Bifidobacteria* and *Lactobacilli* probiotic treatment can modulate infant microbiota composition during early life (Mohan et al., [@B87]; Stratiki et al., [@B127]; Lahtinen et al., [@B72]) as well as stimulate the growth of other beneficial indigenous bacterial species in animals and humans (Tannock et al., [@B134]; Sui et al., [@B130]; Ohashi et al., [@B95]). Modulation of colonization by probiotic bacteria can prevent harmful pathogens from persisting in the intestinal tract, thereby facilitating clearance by the immune system. In addition, some probiotic bacteria produce bacteriocins that inhibit the growth of pathogenic bacteria (Heng et al., [@B56]). For example, a bacteriocin produced by *L. acidophilus* La-14 repressed the growth of *L. monocytogenes* (Todorov et al., [@B138]), consistent with previous findings with other probiotic species against mycobacterium (Todorov et al., [@B137]).

![**A summary of probiotic biological effects**.](fphar-03-00171-g001){#F1}

Another mechanism of probiotic action is directed at the epithelial surface where they modulate the integrity of the epithelial cell barrier and regulate the function and expression of tight junction proteins and mucus secretion (Caballero-Franco et al., [@B26]). The probiotic *Escherichia coli* strain Nissle 1917 was shown to increase both ZO-2 expression and PKC signaling associated with enhanced barrier function in T84 epithelial cells (Zyrek et al., [@B161]). Increased transepithelial resistance as well as enhanced tight junction protein phosphorylation of actinin and occludin was detected following treatment of enteroinvasive *E. coli* infected cells with live *Streptococcus thermophilus* and *Lactobacillus acidophilus* (Resta-Lenert and Barrett, [@B111]). Probiotics also produce significant quantities of short-chain fatty acids (SCFA) following fermentation of dietary fiber and exert potent anti-inflammatory and epithelial activities (O'Keefe et al., [@B96]; Macia et al., [@B79]). Butyrate, a common SCFA, was found to modulate the expression of certain tight junction proteins such as cingulin, ZO proteins, and occludin to improve the epithelial barrier integrity (Bordin et al., [@B19]; Peng et al., [@B103]). Another SCFA, acetate, has been shown to reduce inflammatory lesions in animal models of asthma and colitis (Maslowski et al., [@B85]). Neutrophils express the G protein-coupled receptors GPR41 and GPR43 that can bind SCFAs and mediate their anti-inflammatory effects (Maslowski et al., [@B85]). This effect for SCFAs was demonstrated through modulation of NFκB and cytokine activities *in vitro* (Tedelind et al., [@B136]). It has also been proposed that SCFAs exhibit histone deacetylase inhibitory properties that modify chromatin structure/function and downstream gene expression (Licciardi et al., [@B77]).

Various studies have found that probiotic bacteria can modulate both innate and adaptive immunity. The activation of TLRs by microbes initiates the immune response which can result in systemic and mucosal effects (Castillo et al., [@B27]). *Lactobacilli* attenuated pro-inflammatory responses by regulating NFκB activity (Yang et al., [@B156]), while other probiotics reduced TNF-α induced NFκB activation in a TLR9-dependent manner (Ghadimi et al., [@B49]). Probiotic bacteria also modulated DC maturation toward an anti-inflammatory IL-10 profile (Borchers et al., [@B18]). Moreover, human monocyte-derived DCs (MoDCs) treated with a probiotic culture supernatant released IL-10 that enabled the differentiation and survival of Treg (Rimoldi et al., [@B113]). *B. animalis* and *B. longum* were shown to induce IFN-γ and TNF-α release by DCs while in contrast, only *B. bifidum* could induce Th17 cell activation through the release of IL-17 by DCs (Lopez et al., [@B78]). LGG was also found to be a potent inducer of DC maturation while *L. delbrueckii* stimulated the secretion of both pro-inflammatory cytokines and IL-10 (Elmadfa et al., [@B41]).

There is a significant body of evidence demonstrating that probiotics modulate the Th1/Th2 balance to prevent the development of inflammatory diseases such as allergy. Human peripheral blood mononuclear cells (PBMCs) from allergic patients *in vitro* treated with several lactic acid bacteria including *L. plantarum*, *L. lactis*, *L. casei*, and LGG prior to stimulation with house dust mite had reduced Th2 responses characterized by lower IL-4 and IL-5 secretion (Pochard et al., [@B104]). Several other studies have shown similar cytokine effects, with LGG and *L. bulgaricus* inducing IL-1β, IL-6, IL-8, and TNF-α by PBMCs *in vitro* (Niers et al., [@B92]) while other lactic acid bacteria increased IFN-γ, TNF-α as well as IL-10 (Miettinen et al., [@B86]). The role of probiotics on Treg activity has also been reported. Both LGG and *B. lactis* Bb12 suppressed allergic symptoms in a mouse model of asthma by inducing TGF-β secreting Tregs (Feleszko et al., [@B43]). In another study, *L. acidophilus* W55 but not *L. plantarum* W62 was able to induce functional FoxP3+ Treg from CD25− cells in PBMCs from healthy adults, further supporting the species-specific effects of probiotics (de Roock et al., [@B34]). Other effects of probiotics that make them suitable for modulation of allergic disease include stimulation of mucosal IgA levels as well as allergen-specific B and T cell responses (Prescott and Bjorksten, [@B105]; Marschan et al., [@B83]; Maldonado Galdeano et al., [@B82]).

Evidence for Probiotic Effects in Animal Models of Allergic Disease
===================================================================

The evaluation of probiotics in RCTs for the prevention and/or treatment of allergic disease are often the result of mechanistic data provided by *in vitro* experiments as well as animal models. Many studies have examined the use of probiotics in animal models of allergic disease, often with convincing results. Prebiotics, defined as a selectively fermented ingredient that allows specific changes in the composition and/or activity of intestinal microbiota to confer a health benefit on the host (Charalampopoulos and Rastall, [@B28]), are often given in combination with probiotics (termed symbiotic) however the biological effects of prebiotics are more limited and are not described in this review.

Probiotics have been shown to be effective in animal models of atopic dermatitis (eczema). Oral *L. rhamnosus* CGMCC supplementation to pregnant mice was shown to prevent the development of atopic dermatitis (eczema) when the newborns were also treated for the first 12 weeks, with reduced clinical symptoms, total plasma IgE levels and enhanced IFN-γ in skin biopsies (Curran, [@B32]). However, this effect was not observed when treatment was started 1 week after the onset of disease. Similar effects were observed by these authors when *L. johnsonii* NCC533 (La1) was given to mice for 4 weeks during the weaning period (Charalampopoulos and Rastall, [@B28]). In a dog model of atopic dermatitis, reduction in allergen-specific IgE levels were detected following treatment with LGG but no significant changes in clinical signs were observed (Cook et al., [@B30]). Using NC/Nga mice, several studies with various lactobacilli strains have shown beneficial effects in the prevention of atopic dermatitis-like symptoms, including increased sIgA production (Abrahamsson et al., [@B1]), reduced IgE (Wakabayashi et al., [@B147]), upregulated IL-10 (Abrahamsson et al., [@B1]), and reduced Th2 cytokine secretion *in vitro* (Klewicka et al., [@B69]), suggesting that probiotics mediate their activity through several mechanisms. In a mouse model of atopic dermatitis induced by house dust mite and dinitrochlorobenzene, treatment with a probiotic mixture containing *L. acidophilus*, *L. casei*, *L*, *reuteri*, *B. bifidum*, and *Streptococcus thermophilus* inhibited clinical progression as well as attenuating total and allergen-specific IgE levels, IL-4, IL-5, IL-10, and IL-13 levels associated with increased CD4+FoxP3+ Tregs in the ear (Klewicka et al., [@B69]).

The mouse allergic airway disease (AAD) model of human asthma is frequently used for the examination of probiotic effectiveness. Hougee et al. ([@B58]) revealed that of 6 probiotic strains tested in an OVA AAD model, *B. breve* M-16V had the most potential due to the ability to improve lung function as well as reduce eosinophil numbers, OVA-specific IgE, IL-4, IL-5, and IL-10 levels in the bronchoalveolar lavage fluid (BALF). Treatment of mice with *L. casei plantarum* Lcr35 prior to OVA sensitization was found to prevent the development of airway hyperresponsiveness (AHR), BALF eosinophils as well as total serum IgE levels compared to mice treated with Lcr35 after OVA sensitization but before OVA challenge (Yu et al., [@B158]). Not all probiotics have been shown to be effective however. In one study, *L. reuteri* but not *L. salivarius* was able to significantly attenuate AAD by way of reduced airway eosinophils, AHR and TNF-α, IL-5 and IL-13 levels in the BALF (Forsythe et al., [@B47]). Subsequent studies by these authors showed that *L. reuteri* induced CD4+CD25+FoxP3+ Treg in the spleen of treated mice that were able to prevent the development of AAD following adoptive transfer into OVA-sensitized mice (Karimi et al., [@B66]). These results were in support of the study by Feleszko et al. ([@B43]) where administration of LGG but not *B. lactis* Bb12 was able to suppress allergen-induced T cell proliferation associated with upregulated TGF-β secreting T cells and FoxP3+ cells in the lymph nodes. LGG was also shown to suppress AAD in mouse offspring following maternal administration along with reduced expression of TNF-α, IL-5, and IL-10 but not IL-14 or IL-14 by splenic lymphocytes (Blumer et al., [@B17]). Recent evidence suggests that maternal supplementation with beneficial bacteria may induce epigenetic changes in the progeny, with evidence showing that the beneficial farm-derived *Acinetobacter lwoffii* F78 bacterium was able to prevent the development of an asthma phenotype via histone modification at the *IFNG* promoter (Brand et al., [@B23]).

Less data is available from animal models of food allergy although existing evidence supports a role for probiotics. In a pig model of egg allergy, *Lactococcus lactis* pre-treatment was shown to reduce clinical symptoms, lower IL-4 and IL-10 levels in mitogen-stimulated mononuclear cell supernatants but lower IgG1/IgG2 and IgE/IgG2 ratios indicating a Th1 bias compared to untreated pigs (Rupa et al., [@B115]). The use of the probiotic mixture VSL\#3 also suppressed the allergic response following shrimp tropomyosin sensitization in mice (Schiavi et al., [@B118]). Reduced histamine release, symptom scores, and IgE levels were associated with VSL\#3 treatment as well as lower IL-4, IL-5, IL-3 but higher IFN-γ, TGF-β, and IL-10 levels in the intestine. Other studies using the OVA model of egg allergy have demonstrated anti-allergic effects for several probiotic species including *L. acidophilus* (Kim et al., [@B67]; Finamore et al., [@B44]), *B. lactis* (Kim et al., [@B67]), LGG (Finamore et al., [@B44]), and *L. lactis* (Zuercher et al., [@B160]). *L. casei* Shirota was unable to suppress peanut allergic responses in rats characterized by increased levels of both IgG and IgE as well as IFN-γ and IL-4 levels secreted by *in vitro* stimulated splenic and mesenteric lymph node cells (de Jonge et al., [@B33]).

Evidence for the Clinical Effects of Probiotics in Allergic Disease
===================================================================

Over the past 15 years, a number of studies have examined the clinical benefit of probiotics for the prevention or treatment of allergic disease. Most of these have focused on eczema since this is frequently the first manifestation of allergic disease (refer Table [2](#T2){ref-type="table"} for a summary of probiotic bacteria with beneficial effects in eczema), while a few studies have looked at other outcomes such as asthma and food allergy.

###### 

**Probiotics demonstrating a beneficial effect in clinical studies of eczema**.

  Type of clinical study   Probiotic
  ------------------------ ------------------------------------------------------------------------
  Treatment                *Lactobacillus rhamnosus* GG
                           *Lactobacillus rhamnosus* HN001
                           *Lactobacillus sakei* KCTC
                           *Lactobacillus acidophilus* La-5
                           *Lactobacillus acidophilus[\*](#tfn1){ref-type="table-fn"}*
                           *Lactobacillus salivarius* LS01
                           *Lactobacillus fermentum* VR1
                           *Bifidobacterium lactis* Bb12
                           *Bifidobacterium lactis* UABLA-12[\*\*](#tfn2){ref-type="table-fn"}
                           *Bifidobacterium bifidum*
  Prevention               *Lactobacillus rhamnosus* GG
                           *Lactobacillus rhamnosus* LC705
                           *Lactobacillus paracasei* F19
                           *Bifidobacterium breve* Bb99
                           *Propionibacterium freudenreichii[\*\*\*](#tfn3){ref-type="table-fn"}*

*\*In combination with B. bifidum*, *L. casei*, *L. salivarius*.

*\*\*In combination with *L. acidophilus* DDS-1 and fructo-oligosaccharides (prebiotic)*.

*\*\*\*In combination with galacto-oligosaccharides (prebiotic)*.

Allergy treatment studies
-------------------------

Table [3](#T3){ref-type="table"} summarizes the major outcomes of probiotic intervention studies for the treatment of eczema. Initial studies of probiotic treatment with LGG, *Bifidobacterium lactis* Bb12 or *B. breve* M-16V for up to 8 weeks demonstrated improved eczema symptoms in infants and children compared to placebo treatment, although these involved relatively small sample sizes (Majamaa and Isolauri, [@B81]; Isolauri et al., [@B60]; Hattori et al., [@B53]). In the study by Weston et al. ([@B150]) significantly reduced eczema severity (SCORAD) was observed over an 8-week *L. fermentum* VR1-003PCC treatment period, however this was not different when compared to the placebo group. In contrast, these effects of probiotics have not been confirmed in more recent and larger scale trials (Rosenfeldt et al., [@B114]; Viljanen et al., [@B145]; Brouwer et al., [@B24]; Folster-Holst et al., [@B46]; Sistek et al., [@B123]; Gruber et al., [@B52]). However, despite the lack of a beneficial effect in these studies, subgroup analysis revealed improved SCORAD following LGG (Viljanen et al., [@B145]) or a combined *L. rhamnosus* HN001 and *B. lactis* HN019 (Sistek et al., [@B123]) treatment in children with atopy/IgE-associated eczema. In the study by Viljanen et al. ([@B146]), the clinical effects observed for LGG were associated with low IL-6 and C-reactive protein (CRP) levels indicative of low-grade inflammation; it was suggested that this may trigger anti-inflammatory responses such as elevated IgA and IL-10 to suppress the ongoing allergic/inflammatory process.

###### 

**Summary of probiotic intervention studies for the treatment of eczema**.

  Probiotic used                                                                                                                                                                    Treatment period                 Major outcomes                                                                      Study
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------- -------------------------------
  *B. breve* M-16V                                                                                                                                                                  4 weeks (*N* = 15 infants)       Improved allergic symptoms                                                          Hattori et al. ([@B53])
                                                                                                                                                                                                                     Increased *Bifidobacterium* numbers                                                 
  *B. lactis* Bb12 or LGG                                                                                                                                                           8 weeks (*N* = 27 infants)       Improvement in skin condition                                                       Isolauri et al. ([@B60])
  LGG 5 × 10^8^ CFU/g                                                                                                                                                               4 weeks (*N* = 27 infants)       Improved clinical score                                                             Majamaa and Isolauri ([@B81])
  *L. fermentum* VRI-033 PCC 1 × 10^9^ CFU                                                                                                                                          16 weeks (*N* = 56 infants)      Reduced SCORAD                                                                      Weston et al. ([@B150])
                                                                                                                                                                                                                     Improved skin condition                                                             
  *L. rhamnosus* or LGG 3 × 10^8^ CFU/g                                                                                                                                             12 weeks (*N* = 50 infants)      No effect on SCORAD                                                                 Brouwer et al. ([@B24])
  LGG 10 × 10^9^ CFU                                                                                                                                                                8 weeks (*N* = 54 infants)       No difference in clinical symptoms, immunological parameters, and quality of life   Folster-Holst et al. ([@B46])
  LGG 5 × 10^9^ CFU                                                                                                                                                                 12 weeks (*N* = 54 infants)      No difference in symptoms, IgE levels                                               Gruber et al. ([@B52])
  *L. rhamnosus* 19070-2 and *L. reuteri* DSM122460 1 × 10^10^ CFU                                                                                                                  6 weeks (*N* = 43 children)      Improved clinical symptoms                                                          Rosenfeldt et al. ([@B114])
  LGG (5 × 10^9^ CFU) or MIX (LGG, 5 × 10^9^ CFU; *L. rhamnosus* LC705, 5 × 10^9^ CFU; *B. breve* Bbi99, 2 × 10^8^ CFU; and *P. freudenreichii* ssp. shermanii JS, 2 × 10^9^ CFU)   4 weeks (*N* = 230 children)     Improved clinical symptoms in LGG group                                             Viljanen et al. ([@B145])
  *L. sakei* 5 × 10^9^ CFU                                                                                                                                                          12 weeks (*N* = 75 children)     Decreased SCORAD, improved clinical effects                                         Woo et al. ([@B154])
  *B. bifidum*, *L. acidophilus*, *L. casei*, and *L. salivarius* 2 × 10^9^ CFU                                                                                                     8 weeks (*N* = 40 children)      Reduced SCORAD, total IgE                                                           Yesilova et al. ([@B157])
  *B. breve* M-16V and a GOS/FOS mixture                                                                                                                                            12 weeks (*N* = 90 infants)      No difference in SCORAD                                                             van der Aa et al. ([@B142])
  1.3 × 10^9^ CFU/100 ml                                                                                                                                                                                             Modulated intestinal microbiota                                                     
  *L. salivarius* and prebiotic or prebiotic alone 2 × 10^9^ CFU                                                                                                                    8 weeks (*N* = 60 children)      Reduced SCORAD, improved clinical condition, less medication use                    Wu et al. ([@B155])
  *L. casei* 1 × 10^8^ CFU/ml                                                                                                                                                       12 months (*N* = 187 children)   No difference in asthma symptoms, lower incidence of rhinitis                       Giovannini et al. ([@B50])
  *L. gasseri* A5 2 × 10^9^ CFU/capsule                                                                                                                                             8 weeks (*N* = 105 children)     Decreased clinical symptoms, reduced allergic cytokines                             Chen et al. ([@B29])

Two studies have reported a positive effect of probiotic supplementation for the treatment of eczema. An 8-week treatment with the probiotic/prebiotic mixture containing *L. acidophilus* DDS-1, *B. lactis* UABLA-12, and fructo-oligosaccharides (FOS) was observed to reduce SCORAD to a greater extent than placebo (Gerasimov et al., [@B48]) while a 12-week *L. sakei* KCTC 10755BP treatment in young children also lowered SCORAD and improved mean disease activity by three-fold over placebo-treated children (Woo et al., [@B154]). In the recent study by Yesilova et al. ([@B157]), children aged 1--3 years with a history of eczema were treated with a combination of *B. bifidum*, *L. acidophilus*, *L. casei*, *and L. salivarius* for 8 weeks and found reductions in SCORAD as well as serum cytokines IL-5, IL-6, IFN-γ, and total serum IgE levels, but not IL-2, IL-4, IL-10, or TNF-α compared to the placebo group. However, the use of a combined probiotic and prebiotic formulation (synbiotic) containing *B. breve* M-16V and a mixture of galacto- and fructo-oligosaccharides (GOS/FOS) were unable to improve eczema severity compared to placebo although an improved SCORAD was observed for infants with IgE-associated eczema (van der Aa et al., [@B142]). In a study by Wu et al. ([@B155]), treatment of children suffering moderate to severe eczema with a combination of *L. salivarius* and FOS for 8 weeks resulted in significantly reduced severity scores compared to FOS only, although no placebo group was used for baseline comparison. A similar result was found in adults treated with *L. salivarius* LS01 for 16 weeks, with significantly lower SCORAD compared to placebo as well as decreased IFN-γ, IL-2, and Th1/Th2 cytokine ratio (Drago et al., [@B39]).

The evidence for a beneficial effect of probiotics in the treatment of eczema based on several systematic reviews and meta-analyses are inconclusive (Boyle et al., [@B20]; Lee et al., [@B75]; Tang et al., [@B133]). In particular, the Cochrane meta-analysis (Boyle et al., [@B20]) found no significant reduction in eczema symptoms or severity by probiotics compared to placebo. Moreover, analysis of those participants with atopy or with severe disease was not able to identify a subset of patients that may benefit from probiotic therapy. Explanations for the lack of a probiotic treatment effect could be due to the significant heterogeneity between studies, both in the study populations and the selection of probiotic strains used. It is possible that the activity of potentially beneficial probiotic bacteria may be masked in pooled analyses. Therefore, the ability of probiotics to improve eczema outcomes cannot be completely excluded.

In the context of food allergy, tolerance to food antigens during infancy is a critical step in the development of the immune system. Given the ability of probiotics to modulate mucosal responses such as IgA production, DC, and Treg numbers as well as maintaining the GIT epithelial barrier integrity, it is no surprise that they have been investigated in food allergic individuals (Isolauri et al., [@B61]; Majamaa and Isolauri, [@B81]; Pelto et al., [@B100]). Currently, no evidence has been shown to suggest that probiotics can induce clinical tolerance to food antigens. However, the few studies that have examined whether probiotic treatment can modify the natural course of food allergy have not demonstrated an effect. In a randomized double-blind placebo-controlled study of 119 infants with challenge confirmed cow's milk allergy, supplementation with *L. casei* CRL431 and *B. lactis* Bb12 for 12 months did not affect acquisition of tolerance to cow's milk (Hol et al., [@B57]). In another study in children less than 3 years of age sensitized to egg, peanut, or cow's milk, treatment with a probiotic mix containing *Lactobacillus* and *Bifidobacterium* species for 3 months failed to influence sensitization (SPT size or allergen-specific IgE levels) or *ex vivo* immune responses (Flinterman et al., [@B45]). In addition, one study that examined SCORAD outcomes in children with eczema and cow's milk allergy also found no effect of probiotic treatment (Viljanen et al., [@B145]).

In contrast to those studies on eczema outcomes, there are limited studies on the effect of probiotic treatment for asthma. In a small study, *L. acidophilus* treatment had no impact on clinical asthma in adults (Wheeler et al., [@B151]). Furthermore, adults given *B. breve* M-16V and GOS/FOS (prebiotic) did not show any improvement in lung function or bronchial inflammation although IL-5 levels were reduced (van de Pol et al., [@B141]). A complicating factor is that several studies include mixed populations involving patients with asthma and allergic rhinitis rather than either condition alone. This makes demonstration of any real benefit more difficult. Indeed, while no benefit was observed in studies involving heterogeneous populations treated with *L. casei* (Giovannini et al., [@B50]) or LGG (Helin et al., [@B55]), one study of children with asthma/allergic rhinitis treated with *L. gasseri* showed significant improvements in clinical symptoms as well as reduced allergic cytokine levels such IL-13 (Chen et al., [@B29]). In summary, the conflicting data from the few reported studies do not support the use of probiotics for the treatment of asthma.

Allergy prevention studies
--------------------------

Prevention of allergic disease remains the greatest challenge for clinicians. While a paucity and evidence -- mainly inconclusive -- exists for the use of probiotics in the treatment of allergic disease, several clinical trials have been successful in the use of probiotics for the prevention of allergic disease. At present, a total of 14 randomized controlled trials evaluating various probiotics have been reported, mostly involving infants of families with a history of allergic disease (summarized in Table [4](#T4){ref-type="table"}; Kalliomaki et al., [@B64]; Rautava et al., [@B108]; Abrahamsson et al., [@B2]; Kukkonen et al., [@B71]; Taylor et al., [@B135]; Huurre et al., [@B59]; Kopp et al., [@B70]; Wickens et al., [@B153]; Niers et al., [@B91]; Soh et al., [@B125]; West et al., [@B149]; Dotterud et al., [@B38]; Kim et al., [@B68]; Boyle et al., [@B21]).

###### 

**Summary of probiotic intervention studies for the prevention of eczema**.

  Probiotic used                                                                                                                                                                       Treatment period                                                                                                                       Outcomes                                                                                                                                  Study
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  LGG (1.8 × 10^10^ CFU/day)                                                                                                                                                           Prenatal: 36 weeks until delivery (*N* = 212)                                                                                          No effect on eczema, IgE-associated eczema, and sensitization at 12 months of age                                                         Boyle et al. ([@B21])
  *L. rhamnosus* LPR (2 × 10^7^ CFU/day) and *B. longum* BL999 (1 × 10^7^ CFU/day)                                                                                                     Postnatal: 0--6 months (*N* = 253)                                                                                                     No difference in incidence of eczema, sensitization, and IgE levels at 12 months of age                                                   Soh et al. ([@B125])
  LGG and *B. lactis* Bb12 (1 × 10^10^ CFU/day)                                                                                                                                        Postnatal: 0--12 months (*N* = 72)                                                                                                     No difference in eczema, sensitization at 12 months of age                                                                                Rautava et al. ([@B108])
                                                                                                                                                                                                                                                                                                                              Increased cow's milk-specific IgA secreting cells                                                                                         
  *L. acidophilus* LAVRI-A1 (3 × 10^10^ CFU/day)                                                                                                                                       Postnatal: 0--6 months (*N* = 172)                                                                                                     No difference in eczema, increased sensitization, and wheezing                                                                            Taylor et al. ([@B135])
  *L. paracasei* F19 (1 × 10^8^ CFU/day) or placebo                                                                                                                                    Postnatal: 6--15 months (*N* = 179)                                                                                                    Decreased in eczema, no difference in asthma, IgE levels, or sensitization                                                                West et al. ([@B149])
  LGG (1 × 10^10^ CFU/day)                                                                                                                                                             Pre- and postnatal: 2--4 weeks before delivery; 0--6 months after delivery (*N* = 132)                                                 Decreased atopic eczema, no difference in IgE, and skin prick test result at 2 years of age                                               Kalliomaki et al. ([@B64])
  MIX (LGG 5 × 10^9^ CFU/day), *L. rhamnosus* LC705 (5 × 10^9^ CFU/day), *B. breve* Bb99 (2 × 10^8^ CFU/day), *P. freudenreichii* ssp Shermani JS (2 × 10^9^ CFU/day), and prebiotic   Pre- and postnatal: 2--4 weeks before delivery; 0--6 months after delivery (*N* = 925)                                                 Reduction in eczema and IgE-associated eczema, no difference in other allergic outcomes by 2 years of age                                 Kukkonen et al. ([@B71])
  L. *reuteri* ATCC 55730 (1 × 10^10^ CFU/day)                                                                                                                                         Pre- and postnatal: 4 weeks before delivery; 0--12 months after delivery (*N* = 188)                                                   No difference in incidence of eczema, reduced IgE-associated eczema, and sensitization in infants by 2 years of age                       Abrahamsson et al. ([@B2])
  LGG (5 × 10^10^ CFU/day)                                                                                                                                                             Pre- and postnatal: 4--6 weeks before delivery; 0--6 months (0--3 months to breastfeeding mothers, 3--6 months to infants; *N* = 94)   No effect on eczema or sensitization, increased recurrent episodes of wheezing bronchitis at 2 years of age                               Kopp et al. ([@B70])
  *L. rhamnosus* HN001 (6 × 10^9^ CFU/day) or *B. animalis* subsp. *lactis* HN019 (9 × 10^9^ CFU/day)                                                                                  Pre- and postnatal: 5 weeks until delivery; 0--6 months to breastfeeding mothers and 2 years to infants (*N* = 474)                    Reduced eczema in both groups, reduced IgE-associated eczema (HN001 only), no effect on sensitization in either group at 2 years of age   Wickens et al. ([@B153])
  LGG, *L. acidophilus* La-5 and *B. lactis* Bb12 (1 × 10^9^ CFU/day)                                                                                                                  Pre- and postnatal: 36 weeks until delivery, 0--3 months to breastfeeding mothers (*N* = 278)                                          Reduced eczema, no effect on asthma or sensitization                                                                                      Dotterud et al. ([@B38])
  LGG or *B. lactis* Bb12 (1 × 10^10^ CFU/day)                                                                                                                                         Pre- and postnatal: first trimester until delivery; until end of exclusive breastfeeding (*N* = 140)                                   No effect on eczema and sensitization, less sensitization in infants of allergic mothers at 1 year of age (*B. lactis* group)             Huurre et al. ([@B59])
  MIX (*B. bifidum* BGN4, *B. lactis* AD011, and *L. acidophilus* AD031; all 1.6 × 10^9^ CFU/day)                                                                                      Pre- and postnatal: 4--8 weeks before delivery; 0--3 months to mothers and 4--6 months to infants (*N* = 112)                          Reduced eczema, no difference in total IgE, or sensitization                                                                              Kim et al. ([@B68])
  MIX (*B*. *bifidum* W23, *B. lactis* W52 and *L. lactis* W58) (all 1 × 10^9^ CFU/day)                                                                                                Pre- and postnatal: 6 weeks before delivery; 0--12 months to infants (*N* = 102)                                                       Lower parental-reported eczema for the first 3 months, no difference after 3 months                                                       Niers et al. ([@B91])

Timing and duration of the probiotic intervention appears to be major factor in determining their beneficial effects. Nine of the 14 RCTs involved both a prenatal and postnatal intervention period, while four studies evaluated only postnatal and one study examined a prenatal only approach (Boyle et al., [@B21]). For the combined prenatal/postnatal probiotic studies, there was a significant reduction in the cumulative incidence of eczema and/or IgE-associated eczema in six of the nine published RCTs (Kalliomaki et al., [@B64]; Kukkonen et al., [@B71]; Wickens et al., [@B153]; Niers et al., [@B91]; Dotterud et al., [@B38]; Kim et al., [@B68]) by age 2 years. No such effects were reported in the other three studies (Abrahamsson et al., [@B2]; Huurre et al., [@B59]; Kopp et al., [@B70]). Interestingly, of these nine prenatal/postnatal studies, a beneficial effect was found in three of five studies that used LGG with or without other probiotics (LGG (Kalliomaki et al., [@B64]); *L. rhamnosus* LC705, *B. breve* Bb99, and *Propionibacterium freudenreichii*+ the prebiotic GOS (Kukkonen et al., [@B71]); LGG, *L. acidophilus* La-5 and *B. lactis* Bb12 (Dotterud et al., [@B38]). In the other two studies using LGG, one was a study in infants irrespective of a family history of allergic disease (Huurre et al., [@B59]) while the other study by Kopp et al. ([@B70]) found no effect despite utilizing a similar protocol and LGG dose to that of the landmark study by Kalliomaki et al. ([@B64]). A recent meta-analysis of the impact of maternal probiotic supplementation on eczema development found a significantly reduced risk in children by 2--7 years of age with the use of lactobacilli but not with other probiotic species and strains compared to placebo treatment (Doege et al., [@B36]). The remaining four prenatal/postnatal RCTs used a variety of probiotic species or combinations with varying efficacy. Only the study by Abrahamsson et al. ([@B2]) showed no difference in eczema, sensitization, or other allergic diseases at 2 years following *L. reuteri* treatment. Two studies using different probiotic mixtures reported a reduction in eczema at 1 year (Kim et al., [@B68]) and 3 months (Niers et al., [@B91]) -- however in this latter study, the effect at 3 months did not persist and the outcomes were parental-reported, not clinician assessed. Wickens et al. ([@B153]) investigated the effects of two different probiotic interventions in relation to placebo and reported that *L. rhamnosus* HN001 but not *B. animalis* subspecies *lactis* HN013 was able to significantly reduce both eczema and IgE-associated eczema at 2 years. Both of these treatments however had no impact on sensitization status. This supports the view that not all probiotics are the same such that they may elicit unique biological activities. Therefore, selection of probiotic species and strains should be carefully considered in the design of future clinical trials. It is important to note that despite the beneficial effects of probiotics in some of the studies, there were also increased risks of asthma-like symptoms at 2 years in the study by Kopp et al. ([@B70]) and at 7 years in the study by Kalliomaki et al. ([@B65]), suggesting that it will be critical to follow these cohorts for several years to determine any long-term impact (beneficial or otherwise) of the probiotic effect.

No beneficial effects on eczema or sensitization were found in three of the four studies using a postnatal treatment approach (Rautava et al., [@B108]; Taylor et al., [@B135]; Soh et al., [@B125]) with one study that used *L. acidophilus* LAVRI-A1 demonstrating an increased risk of both IgE-associated eczema and atopic sensitization at 1 year of age (Taylor et al., [@B135]). The remaining study found a reduced cumulative incidence of eczema at 13 months with *L. paracasei* F19 (West et al., [@B149]). Overall, these studies suggest that a postnatal probiotic treatment alone may be insufficient in reducing the clinical symptoms of allergic disease and highlights that the importance of the early life period in modulating microbiota and/or immune function begins prior to birth. In addition, the differences in study designs make it difficult to draw meaningful conclusions as two studies recruiting high-risk infants with a family history of allergic disease (Taylor et al., [@B135]; Soh et al., [@B125]) while the other two studies included formula-fed infants irrespective of allergic disease family history (Rautava et al., [@B108]; West et al., [@B149]). In contrast, the only study to date that evaluated a prenatal only probiotic approach (using LGG) showed no evidence for a beneficial effect on eczema or sensitization at 12 months (Boyle et al., [@B21]). This suggests that a prenatal alone intervention is insufficient and that inclusion of a postnatal treatment period is required. Alternatively, probiotic species/strains other than LGG may be effective for the prevention of eczema.

Breastfeeding is one parameter that may be critical in mediating probiotic effects. Infants who were breastfed by mothers treated with probiotics during pregnancy and breastfeeding benefited the most, even when probiotics were not administered directly to them (Dotterud et al., [@B38]). Breast milk has important immunoregulatory factors such as TGF-β and IgA which can help protect against the development of allergic disease (Rautava et al., [@B108]). The biological mechanisms underpinning these outcomes are not well understood and require further investigation.

In summary, the use of probiotic bacteria for the prevention and/or treatment of allergic disease have shown promising results to date. However, the validity of these findings need to be confirmed by further randomized controlled trials. In particular, for eczema, the timing of the probiotic intervention appears to be important, with a prenatal component critical for protective effects (Osborn and Sinn, [@B97]). Furthermore, a combined prenatal with early postnatal treatment may be equally effective (Boyle et al., [@B21]) while a postnatal alone approach less successful. From the existing literature, it is clear that several variables can have an impact on the potential beneficial effects observed, including the species and strain of probiotic used, geographical differences in the populations studied as well as the dose and duration of administration. These differences make drawing conclusions about the effectiveness of probiotics more difficult. Further studies are therefore required to determine the optimal dose, bacterial strain(s), timing for intervention, and patient populations that would provide optimal effects in the prevention and/or treatment of allergic disease.

Conclusion
==========

Studies suggest a potential role for selected probiotics in the prevention of eczema, especially IgE-associated eczema. The efficacy of probiotics for the treatment of allergic disease however requires further examination. Careful selection of appropriate probiotic bacteria for future studies will be important, which may be aided by *in vitro*, preclinical and pilot studies. In addition, there is insufficient evidence that probiotics may be of benefit for the prevention of other allergic conditions. An important limitation of meta-analyses of studies evaluating probiotics for the prevention of allergic diseases is that data have been pooled from studies conducted with a variety of different probiotic combinations. Further clinical studies using the most effective study designs incorporating prenatal/postnatal treatment and selection of appropriate probiotic bacteria are required to validate the findings of earlier studies. Understanding the mechanisms of protection in allergic disease will greatly assist in developing more targeted strategies for the prevention or treatment of allergic disease.
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